vs
Side-by-side financial comparison of ELECTRO SENSORS INC (ELSE) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $2.8M, roughly 2.0× ELECTRO SENSORS INC). ELECTRO SENSORS INC runs the higher net margin — 3.7% vs -507.8%, a 511.5% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs 14.8%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs 10.8%).
Polar Electro Oy is a Finnish manufacturer of sports training computers, particularly known for developing the world's first wireless heart rate monitor.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
ELSE vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8M | $5.5M |
| Net Profit | $103.0K | $-27.9M |
| Gross Margin | 50.3% | — |
| Operating Margin | -0.3% | -516.0% |
| Net Margin | 3.7% | -507.8% |
| Revenue YoY | 14.8% | 171.3% |
| Net Profit YoY | -48.8% | -48.3% |
| EPS (diluted) | $0.03 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8M | $5.5M | ||
| Q3 25 | $2.7M | $0 | ||
| Q2 25 | $2.4M | $2.0M | ||
| Q1 25 | $2.2M | $2.3M | ||
| Q4 24 | $2.4M | $2.0M | ||
| Q3 24 | $2.5M | $1.8M | ||
| Q2 24 | $2.2M | $1.1M | ||
| Q1 24 | $2.2M | $3.4M |
| Q4 25 | $103.0K | $-27.9M | ||
| Q3 25 | $208.0K | $-32.7M | ||
| Q2 25 | $59.0K | $-26.9M | ||
| Q1 25 | $-64.0K | $-21.5M | ||
| Q4 24 | $201.0K | $-18.8M | ||
| Q3 24 | $238.0K | $-25.5M | ||
| Q2 24 | $-4.0K | $-20.9M | ||
| Q1 24 | $11.0K | $-24.1M |
| Q4 25 | 50.3% | — | ||
| Q3 25 | 53.1% | — | ||
| Q2 25 | 51.2% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 50.4% | — | ||
| Q2 24 | 47.2% | — | ||
| Q1 24 | 48.1% | — |
| Q4 25 | -0.3% | -516.0% | ||
| Q3 25 | 6.6% | — | ||
| Q2 25 | -0.1% | -1347.1% | ||
| Q1 25 | -7.5% | -930.5% | ||
| Q4 24 | 1.3% | -985.8% | ||
| Q3 24 | 6.9% | -1448.4% | ||
| Q2 24 | -4.8% | -1915.4% | ||
| Q1 24 | -4.5% | -713.3% |
| Q4 25 | 3.7% | -507.8% | ||
| Q3 25 | 7.6% | — | ||
| Q2 25 | 2.5% | -1353.6% | ||
| Q1 25 | -2.9% | -935.2% | ||
| Q4 24 | 8.4% | -929.0% | ||
| Q3 24 | 9.5% | -1427.5% | ||
| Q2 24 | -0.2% | -1882.0% | ||
| Q1 24 | 0.5% | -705.4% |
| Q4 25 | $0.03 | $-0.08 | ||
| Q3 25 | $0.06 | $-0.09 | ||
| Q2 25 | $0.02 | $-0.09 | ||
| Q1 25 | $-0.02 | $-0.08 | ||
| Q4 24 | $0.06 | $-0.07 | ||
| Q3 24 | $0.07 | $-0.10 | ||
| Q2 24 | $0.00 | $-0.09 | ||
| Q1 24 | $0.00 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.6M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $14.8M | $246.9M |
| Total Assets | $15.7M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.6M | $319.8M | ||
| Q3 25 | $10.6M | $297.3M | ||
| Q2 25 | $10.2M | $312.8M | ||
| Q1 25 | $10.0M | $116.6M | ||
| Q4 24 | $10.0M | $139.0M | ||
| Q3 24 | $10.3M | $157.7M | ||
| Q2 24 | $9.9M | $172.7M | ||
| Q1 24 | $10.1M | $124.0M |
| Q4 25 | $14.8M | $246.9M | ||
| Q3 25 | $14.7M | $219.0M | ||
| Q2 25 | $14.4M | $248.7M | ||
| Q1 25 | $14.3M | $55.1M | ||
| Q4 24 | $14.3M | $71.5M | ||
| Q3 24 | $14.1M | $88.8M | ||
| Q2 24 | $13.8M | $108.9M | ||
| Q1 24 | $13.8M | $53.8M |
| Q4 25 | $15.7M | $343.3M | ||
| Q3 25 | $15.7M | $316.6M | ||
| Q2 25 | $15.2M | $333.3M | ||
| Q1 25 | $15.1M | $138.4M | ||
| Q4 24 | $14.9M | $160.4M | ||
| Q3 24 | $15.0M | $180.2M | ||
| Q2 24 | $14.5M | $200.4M | ||
| Q1 24 | $14.5M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $20.0K | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 0.19× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.0K | $-26.7M | ||
| Q3 25 | $395.0K | $-24.2M | ||
| Q2 25 | $277.0K | $-20.2M | ||
| Q1 25 | $-30.0K | $-22.0M | ||
| Q4 24 | $-277.0K | $-18.3M | ||
| Q3 24 | $362.0K | $-21.6M | ||
| Q2 24 | $-158.0K | $-21.5M | ||
| Q1 24 | $202.0K | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | $389.0K | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-298.0K | $-18.3M | ||
| Q3 24 | $358.0K | $-21.6M | ||
| Q2 24 | $-184.0K | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -12.4% | -905.5% | ||
| Q3 24 | 14.3% | -1210.9% | ||
| Q2 24 | -8.3% | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.9% | 0.1% | ||
| Q3 24 | 0.2% | 2.0% | ||
| Q2 24 | 1.2% | 18.1% | ||
| Q1 24 | 0.0% | 4.1% |
| Q4 25 | 0.19× | — | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 4.69× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -1.38× | — | ||
| Q3 24 | 1.52× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 18.36× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
